Skip to main content

Table 5 Validation parameters to confirm the built model

From: Computational and pharmacokinetics studies of 1,3-dimethylbenzimidazolinone analogues of new proposed agent against Alzheimer's disease

Validation bounds

Mathematical expression

Threshold

Model

Comment

Ref

Friedman LOF

\(\frac{{{\text{SEE}}}}{{\left( {1 - \frac{c + d \times p}{N}} \right)^{2} }}\)

Significantly low

0.0268

Passed

[24]

R2

\(1 - \left[ {\frac{{\sum \left( {Y_{\exp } - Y_{{{\text{pred}}}} } \right)^{2} }}{{\sum \left( {Y_{\exp } - Y_{{{\text{train}}}} } \right)^{2} }}} \right]\)

\(R^{2} > 0.6\)

0.9062

Passed

[24]

\(R_{{{\text{adj}}}}^{2}\)

\(\frac{{R^{2} - p\left( {n - 1} \right)}}{n - p - 1}\)

\(R_{{{\text{adj}}}}^{2} > 0.6\)

0.863

Passed

[24]

\(Q_{{{\text{cv}}}}^{2}\)

\(1 - \left[ {\frac{{\sum \left( {Y_{{{\text{pred}}}} - Y_{\exp } } \right)^{2} }}{{\sum \left( {Y_{\exp } - Y_{{{\text{train}}}} } \right)^{2} }}} \right]\)

\(Q_{{{\text{cv}}}}^{2} > 0.6\)

0.788

Passed

[24]

Significant regression

  

Yes

Passed

 

F-value (95\%)

\({\raise0.7ex\hbox{${\frac{{\sum \left( {Y_{{{\text{pred}}}} - Y_{\exp } } \right)^{2} }}{p}}$} \!\mathord{\left/ {\vphantom {{\frac{{\sum \left( {Y_{{{\text{pred}}}} - Y_{\exp } } \right)^{2} }}{p}} {\frac{{\sum \left( {Y_{{{\text{pred}}}} - Y_{\exp } } \right)^{2} }}{N - P - 1}}}}\right.\kern-\nulldelimiterspace} \!\lower0.7ex\hbox{${\frac{{\sum \left( {Y_{{{\text{pred}}}} - Y_{\exp } } \right)^{2} }}{N - P - 1}}$}}\)

F(test) > 2.09

3.001

Passed

[24]

Min exp error for non-significant

  

0.0739

Passed

[17]